liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease-Proceedings of the first Thiopurine Task Force meeting
Vrije University Amsterdam Medical Centre, Amsterdam, The Netherlands.
Guys and St Thomas Hospital, London, UK.
Vrije University Amsterdam Medical Centre, Amsterdam, The Netherlands.
Alfred Hospital, Melbourne, Australia.
Show others and affiliations
2011 (English)In: DIGESTIVE AND LIVER DISEASE, ISSN 1590-8658, Vol. 43, no 4, 270-276 p.Article in journal (Refereed) Published
Abstract [en]

Background: Thiopurines, such as azathioprine and mercaptopurine, are of pivotal importance in the treatment of inflammatory bowel disease. Although these drugs have been used for several decades, still many questions remain unanswered. Aim: To provide an overview of clinically and scientifically challenging topics concerning thiopurine therapy in inflammatory bowel disease treatment. Methods: The first meeting of the Thiopurine Task Force Interest Group was held during the 2009 United European Gastroenterology Week in London (GASTRO2009). The topics of this meeting were of particular clinical and scientific interest. Additional literature was identified by performing a Pubmed search using the search terms inflammatory bowel disease, azathioprine, 6-mercaptopurine and thioguanine. Results: The following topics were discussed: therapeutic drug monitoring; the synergy of thiopurines with aminosalicylates and allopurinol; serious adverse events such as opportunistic infections, hepatotoxicity, carcinogenicity and pancreatitis; prolongation of thiopurines during clinical remission; indications for thiopurines in the postoperative setting; and the potential use of thioguanine. Specific interesting and clinically relevant topics for potential future research are provided. Conclusions: Thiopurines remain central to inflammatory bowel disease treatment, although future studies are required to substantiate a more personalised medicine approach to their use.

Place, publisher, year, edition, pages
Elsevier Science B.V., Amsterdam , 2011. Vol. 43, no 4, 270-276 p.
Keyword [en]
Adverse events, Inflammatory bowel disease, Therapeutic drug monitoring, Thiopurines
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-67972DOI: 10.1016/j.dld.2010.09.001ISI: 000289613800005OAI: oai:DiVA.org:liu-67972DiVA: diva2:414728
Available from: 2011-05-04 Created: 2011-05-04 Last updated: 2012-02-14

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Almer, Sven

Search in DiVA

By author/editor
Almer, Sven
By organisation
Gastroenterology and HepatologyFaculty of Health SciencesDepartment of Endocrinology and Gastroenterology UHL
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 47 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf